# US 8,278,317 B2 · Potassium channel inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,317 B2
- Document ID: US8278317B2
- Status: Granted
- Kind: B2
- Application number: 11/988,393
- Filed: 2006-07-18
- Published: 2009-05-14
- Granted: 2012-10-02
- Earliest claimed: 2005-07-22
- Assignees: Merck Sharp & Dohme Corp.
- Inventors: B. Wesley Trotter; Kausik K. Nanda; Scott E. Wolkenberg; M. Brad Nolt; David Wisnoski
- Web page: https://patentgrep.com/patent/US8278317B2

## CPC

- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/06: Antiarrhythmics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 213/56: Amides
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.

## Claims

### Claim 1

A compound selected from the group consisting of:
N,N-diisopropyl-3-phenyl-4-[(4-phenylbutanoyl)amino]-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-3-phenyl-4-[({[(1S)-1-phenylethyl]amino}carbonyl)amino]-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-3-phenyl-4-[(3-phenylpropanoyl)amino]-2-pyridin-3-ylbutanamide,
4-{([3-(2-fluorophenyl)propanoyl]amino}-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-3-phenyl-4-[(3-phenylbutanoyl)amino]-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-4-({[(3-methylbenzyl)amino]carbonyl}amino)-3-phenyl-2-pyridin-3-ylbutanamide,
4-({[(4-bromobenzyl)amino]carbonyl}amino)-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
4-({[(4-fluorobenzyl)amino]carbonyl}amino)-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-3-phenyl-4-[({[(1R,2S)-2-phenylcyclopropyl]amino}carbonyl)amino]-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-4-[({[1-(1-naphthyl)ethyl]amino}carbonyl)amino]-3-phenyl-2-pyridin-3-ylbutanamide,
4-({[(3-fluorobenzyl)amino]carbonyl}amino)-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
4-[(benzylsulfonyl)amino]-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-4-({[(4-methylbenzyl)amino]carbonyl}amino)-3-phenyl-2-pyridin-3-ylbutanamide,
4-({[(2-fluorobenzyl)amino]carbonyl}amino)-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-3-phenyl-4-{[(2-phenyl-1,3-thiazol-4-yl)acetyl]amino}-2-pyridin-3-ylbutanamide,
4-{[3-(2-chlorophenyl)propanoyl]amino}-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-4-({[(4-methoxybenzyl)amino]carbonyl}amino)-3-phenyl-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-3-phenyl-4-({[(E)-2-phenylvinyl]sulfonyl}amino)-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-3-phenyl-2-pyridin-3-yl-4-({[2-(trifluoromethyl)phenyl]sulfonyl}amino)butanamide,
N,N-diisopropyl-3-phenyl-2-pyridin-3-yl-4-[(3-pyridin-2-ylpropanoyl)amino]butanamide,
N,N-diisopropyl-3-phenyl-4-({[(2-phenylethyl)amino]carbonyl}amino)-2-pyridin-3-ylbutanamide,
4-({[(2-chlorobenzyl)amino]carbonyl}amino)-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
4-{[(cyclohexylamino)carbonyl]amino}-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
4-({[(3-fluorophenyl)amino]carbonyl}amino)-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-4-{[(1-naphthylamino)carbonyl]amino}-3-phenyl-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-3-phenyl-4-[({[(1R)-1-phenylethyl]amino}carbonyl)amino]-2-pyridin-3-ylbutanamide,
4-({[(diphenylmethyl)amino]carbonyl}amino)-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-3-phenyl-4-[({[(1S)-1-phenylethyl]amino}carbonyl)amino]-2-pyridin-3-ylbutanamide,
4-{[(sec-butylamino)carbonyl]amino}-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
4-({[(diphenylmethyl)amino]carbonyl}amino)-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
4-[(2,3-dihydro-1H-inden-2-ylacetyl)amino]-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
4-(acetylamino)-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-3-phenyl-2-pyridin-3-yl-4-({[2-(trifluoromethyl)phenyl]acetyl}amino)butanamide,
4-{[(2-chloro-6-fluorophenyl)acetyl]amino}-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
N-[4-(diisopropylamino)-4-oxo-2-phenyl-3-pyridin-3-ylbutyl]pentanamide,
N,N-diisopropyl-4-{[3-(1-methyl-1H-pyrazol-4-yl)propanoyl]amino}-3-phenyl-2-pyridin-3-ylbutanamide,
methyl 5-{[2-(1,3-benzodioxol-5-yl)ethyl]amino}-5-oxo-3-phenyl-4-pyridin-3-ylpentanoate,
N5-(2-fluorobenzyl)-N1,N1-diisopropyl-3-phenyl-2-pyridin-3-ylpentanediamide,
N1,N1-diisopropyl-3-phenyl-N5-(3-phenylpropyl)-2-pyridin-3-ylpentanediamide,
N1,N1-diisopropyl-3-phenyl-N5-(1-phenylethyl)-2-pyridin-3-ylpentanediamide,
N5-[2-(tert-butylthio)ethyl]-N1,N1-diisopropyl-3-phenyl-2-pyridin-3-ylpentanediamide,
N1,N1-diisopropyl-3-phenyl-N5-(2-phenylethyl)-2-pyridin-3-ylpentanediamide,
N5-(2,3-dihydro-1H-inden-2-yl)-N1,N1-diisopropyl-3-phenyl-2-pyridin-3-ylpentanediamide,
N1,N1-diisopropyl-3-phenyl-N5-[(4-phenylmorpholin-2-yl)methyl]-2-pyridin-3-ylpentanediamide,
N1,N1-diisopropyl-3-phenyl-N5-pyridin-2-yl-2-pyridin-3-ylpentanediamide,
N1,N1-diisopropyl-N5-(1-isopropyl-2-methylpropyl)-3-phenyl-2-pyridin-3-ylpentanediamide,
N5-(1H-benzimidazol-2-ylmethyl)-N1,N1-diisopropyl-3-phenyl-2-pyridin-3-ylpentanediamide,
N5-(3-isopropoxypropyl)-N1,N1-diisopropyl-3-phenyl-2-pyridin-3-ylpentanediamide,
N1,N1-diisopropyl-3-phenyl-2-pyridin-3-yl-N-5-(pyridin-2-ylmethyl)pentanediamide,
methyl 5-{[5-(diisopropylamino)-5-oxo-3-phenyl-4-pyridin-3-ylpentanoyl]amino}pentanoate,
1-tert-butyl 5-methyl 3-phenyl-2-pyridin-3-ylpentanedioate,
methyl 4-(3-cyanophenyl)-5-(diisopropylamino)-5-oxo-3-pyridin-3-ylpentanoate,
methyl 4-(3-bromophenyl)-5-(diisopropylamino)-5-oxo-3-pyridin-3-ylpentanoate,
N1,N1-diisopropyl-N5,N5-dimethyl-3-phenyl-2-pyridin-3-ylpentanediamide,
N1,N1-diisopropyl-N5-methyl-3-phenyl-2-pyridin-3-ylpentanediamide,
methyl 5-(diisopropylamino)-5-oxo-4-pyridin-3-yl-3-pyridin-4-ylpentanoate,
5-methoxy-5-oxo-3-phenyl-2-pyridin-3-ylpentanoic acid,
methyl 5-(diisopropylamino)-5-oxo-4-pyridin-3-yl-3-pyridin-4-ylpentanoate,
methyl 5-(diisopropylamino)-5-oxo-3-phenyl-4-pyridin-2-ylpentanoate,
methyl 5-(diisopropylamino)-5-oxo-4-pyridin-2-yl-3-pyridin-4-ylpentanoate,
methyl 5-(diisopropylamino)-5-oxo-3,4-dipyridin-4-ylpentanoate,
methyl 5-(diisopropylamino)-5-oxo-4-phenyl-3-pyridin-4-ylpentanoate,
methyl 5-(diisopropylamino)-5-oxo-3-phenyl-4-pyridin-4-ylpentanoate,
3-(3-cyanophenyl)-4-({[(2-fluorobenzyl)amino]carbonyl}amino)-N,N-diisopropyl-2-pyridin-3-ylbutanamide,
N-[4-(diisopropylamino)-4-oxo-2-phenyl-3-pyridin-3-ylbutyl]-2-fluoro-N-(methylsulfonyl)phenylalaninamide,
N-[4-(diisopropylamino)-4-oxo-2-phenyl-3-pyridin-3-ylbutyl]-2-fluorophenylalaninamide,
N-(tert-butoxycarbonyl)-N-[4-(diisopropylamino)-4-oxo-2-phenyl-3-pyridin-3-ylbutyl]-2-fluorophenylalaninamide,
N,N-diisopropyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)-3-phenyl-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-4-(2-methyl-2H-tetrazol-5-yl)-3-phenyl-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-4-(1-methyl-1H-tetrazol-5-yl)-3-phenyl-2-pyridin-3-ylbutanamide,
5-hydrazino-N,N-diisopropyl-5-oxo-3-phenyl-2-pyridin-3-ylpentanamide,
N,N-diisopropyl-4-(3-methyl-1,2,4-oxadiazol-5-yl)-3-phenyl-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-4-(5-methyl-1,3-oxazol-2-yl)-3-phenyl-2-pyridin-3-ylbutanamide,
4-cyano-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-4-[(methylsulfonyl)amino]-3-phenyl-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-4-(5-methyl-1,3-oxazol-2-yl)-3-phenyl-2-pyridin-3-ylbutanamide,
5-hydroxy-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylpentanamide,
tert-butyl 4-(diisopropylamino)-4-oxo-2-phenyl-3-pyridin-3-ylbutylcarbamate,
methyl 3-(3-cyanophenyl)-5-(diisopropylamino)-5-oxo-4-pyridin-3-ylpentanoate,
methyl 3-(3-bromophenyl)-5-(diisopropylamino)-5-oxo-4-pyridin-3-ylpentanoate,
5-(diisopropylamino)-5-oxo-3-phenyl-4-pyridin-3-ylpentanoic acid,
N1,N1-diisopropyl-3-phenyl-2-pyridin-3-ylpentanediamide,
methyl 5-(diisopropylamino)-5-oxo-4-phenyl-3-pyridin-3-ylpentanoate,
methyl 5-(diisopropylamino)-5-oxo-4-pyridin-2-yl-3-pyridin-3-ylpentanoate,
methyl 5-(diisopropylamino)-5-oxo-4-pyridin-2-yl-3-pyridin-3-ylpentanoate,
methyl 5-(diisopropylamino)-5-oxo-4-phenyl-3-pyridin-3-ylpentanoate,
methyl 5-(diisopropylamino)-5-oxo-3-phenyl-4-pyridin-3-ylpentanoate,
methyl 5-(diisopropylamino)-5-oxo-3,4-dipyridin-3-ylpentanoate,
methyl 5-(diisopropylamino)-3-(6-methoxypyridin-3-yl)-5-oxo-4-phenylpentanoate,
methyl 5-(diisopropylamino)-5-oxo-3-pyridin-2-yl-4-pyridin-4-ylpentanoate,
methyl 5-(diisopropylamino)-5-oxo-3-pyridin-2-yl-4-pyridin-3-ylpentanoate,
methyl 5-(diisopropylamino)-5-oxo-3,4-dipyridin-2-ylpentanoate, and
methyl 5-(diisopropylamino)-5-oxo-4-phenyl-3-pyridin-2-ylpentanoate, or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A pharmaceutical formulation comprising a pharmaceutically acceptable carrier and the compound of claim 1.

### Claim 3 (depends on 1)

A pharmaceutical composition made by combining the compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 4 (depends on 1)

A method of treating cardiac arrythmia comprising administering a compound of claim 1 with a compound selected from one of the classes of compounds consisting of antiarrhythmic agents having Kv1.5 blocking activities, ACE inhibitors, angiotensin II antagonists, cardiac glycosides, L-type calcium channel blockers, T-type calcium channel blockers, selective and nonselective beta blockers, endothelin antagonists, thrombin inhibitors, aspirin, nonselective NSAIDs, warfarin, factor Xa inhibitors, low molecular weight heparin, unfractionated heparin, clopidogrel, ticlopidine, IIb/IIIa receptor antagonists, 5HT receptor antagonists, integrin receptor antagonists, thromboxane receptor antagonists, TAFI inhibitors and P2T receptor antagonists.
